In 2018, the first case was reported [56] in which a neoadjuvant approach was applied to a patient with unresectable BRAF V600E-mutated ATC, achieving complete tumor resection after the administration of dabrafenib, trametinib, and pembrolizumab, with a survival of at least 16 months and a good quality of life. The gene discussed is BRAF; the disease is neoplasm.